PLEASANTON, Calif., June 21, 2012 (GLOBE NEWSWIRE) -- ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform branded CoolSculpting®, today announced that Robert Tyson has been promoted from Regional Sales Director for the East Region to Vice President of North America Sales.
Mr. Tyson brings over 20 years of healthcare commercial experience to ZELTIQ, mostly in the aesthetic space. He joined ZELTIQ in September 2008 as Director of Sales for the East Region. In this capacity, he won Top Region in 2010 and worked in a boundary-less way to establish the newly-formed Northeast and Southeast Regions. Prior to ZELTIQ, Mr. Tyson held various positions with increasing responsibility with Ulthera, Reliant Technologies, Thermage and Edwards Life Sciences.
"Bobby is a proven, long-time key contributor to ZELTIQ's success," said Mike Genau, President of the North America Franchise (NAF). "We look forward to his leadership in this new role as we continue to advance our commercial activities and deliver on the promise of growing our CoolSculpting business across North America."
CoolSculpting® is a non-surgical, clinically proven procedure designed to selectively reduce fat bulges in problem areas using a patented cooling technology. Physicians report a 95 percent patient satisfaction rate1. It is a procedure cleared by the FDA that gently cools unwanted fat cells in the body to induce a natural, controlled elimination of fat cells. It is designed to reduce fat bulges in treated areas of the body without harming surrounding tissue. CoolSculpting is available through an elite network of CoolSculpting Centers worldwide. Dermatologists, plastic surgeons and leading aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.com.
ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.
1 As reported by physicians; data on file.
CONTACT: MEDIA CONTACT: Shari Gold GOLD PR for ZELTIQ 714-251-0375 INVESTOR RELATIONS: Josh Brumm ZELTIQ, SVP and CFO 925-474-2500 Nick Laudico / Amy Glynn The Ruth Group for ZELTIQ 646-536-7030 / 7023